SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Business
TG Therapeutics, Inc. Announces Exercise Of License Option For Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
September 23, 2014
 · 
4 min read
Drug Development
TG Therapeutics, Inc. Announces Special Protocol Assessment (SPA) Agreement With The FDA For Its First Phase 3 Clinical Trial Of TG-1101 (Ublituximab) In Combination With Imbruvica(R) (Ibrutinib) For Patients With Previously Treated Chronic Lymphocytic Le
September 15, 2014
 · 
6 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 16th Annual Rodman & Renshaw Global Investment Conference
September 8, 2014
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Announces Novel “Chemo-Free” Triple Therapy Combination Clinical Study For Patients With Chronic Lymphocytic Leukemia And Other B-Cell Malignancies
August 15, 2014
 · 
6 min read
Business
TG Therapeutics, Inc. Announces Second Quarter 2014 Financial Results And Business Update
July 22, 2014
 · 
8 min read
Business
TG Therapeutics, Inc. Completes Global Licensing Agreement With Ligand Pharmaceuticals Inc. For The Development Of Inhibitors Of IRAK4
June 24, 2014
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 2014 JMP Securities Healthcare Conference
June 23, 2014
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 2014 Wells Fargo Healthcare Conference
June 17, 2014
 · 
1 min read
Drug Development
TG Therapeutics, Inc.’ TG-1101 (Ublituximab) In Combination With Ibrutinib Demonstrates Compelling Clinical Activity And Safety Profile In Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) And Mantle Cell Lymphoma (MCL)
June 13, 2014
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Announces Clinical Data Presentations For TG-1101 And TGR-1202 At The European Hematology Association Meeting In Milan, Italy
May 23, 2014
 · 
1 min read
Business
TG Therapeutics, Inc. To Host Conference Call On First Quarter 2014 Financial Results And Business Update
May 9, 2014
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Provides Update On A Modified TGR-1202 Formulation And Fed-State Dosing With Data Demonstrating Significantly Higher TGR-1202 Exposure
May 8, 2014
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Announces Clinical Data Presentations At Upcoming Conferences
May 6, 2014
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 39th Annual Deutsche Bank Healthcare Conference
May 5, 2014
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Announces Preclinical Poster Presentations For TGR-1202 At American Association for Cancer Research 2014
April 7, 2014
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Announces $18.1 Million Underwritten Sale Of Common Stock To A Single Institutional Investor
March 12, 2014
 · 
1 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS